Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.

Pharmaceutical

Evotec

Craig Johnstone

Laetitia Rouxel

Cord Dohrmann

Hans-Ulrich Wolf

The Vice Presidents and Senior Vice Presidents at Evotec play critical roles in leading various specialized departments and functions essential to the company's drug discovery and development operations. They drive strategic initiatives across areas such as drug metabolism and pharmacokinetics (DMPK), pharmaceutical development, business development, clinical operations, academic partnerships, global logistics, and corporate communications. Their responsibilities include overseeing research and development (R&D) projects, managing partnerships, ensuring compliance with regulatory standards, and fostering innovation within the company's key scientific and commercial endeavors.

Vice Presidents and Senior Vice Presidents

About

Team members

Other teams at Evotec

Scientific Research & Development

Project and Operations Management